Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy

What Was Tested

The paper reports a study of Octreotide and Somatostatin, published as a randomized controlled trial.

Despite a strong rationale for trials of somatostatin analogs in the treatment of Graves' ophthalmopathy (GO), recent studies have provided conflicting results.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Twenty-nine consecutive euthyroid patients with active GO [clinical activity score (CAS) >or= 3] were enrolled; 25 completed the study.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Octreotide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Octreotide, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Octreotide group a baseline to be compared against.

This was a prospective, randomized, double-blind, placebo-controlled study.

The setting was a single tertiary referral center.

What Was Measured

Topics PubMed links to this paper include Eye, Graves Ophthalmopathy, Octreotide, Somatostatin, Surveys and Questionnaires, Vision Tests and Vision, Ocular.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Octreotide and Somatostatin.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2006 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.